



Indira IVF, BD SurePath join hands to advance cervical cancer screening in India

04 March 2024 | News

Revolutionary liquid based PAP test to significantly increase the detection rate

In a significant move to enhance cervical cancer screening accuracy and accessibility in India, Indira IVF collaborates with BD SurePath. This partnership is aimed at helping improve patient care in the country through BD's revolutionary Liquid-Based cytology PAP test, which significantly increases the detection rate of cervical cancer, enabling its timely treatment and prevention.

Cervical cancer ranks as the second most prevalent cancer among Indian women that claims the lives of nearly 77,348 females each year. With 123,907 new reported cases annually, untimely detection is a primary factor contributing to its critical status as a public health concern. The inaccessibility of advanced screening techniques has resulted in a large number of women being diagnosed at later stages, leading to adverse outcomes. Through this strategic collaboration, this advanced test will now be more widely available across all Indira PathLabs centres.

This DTS Pap test ensures that 100% of the collected sample is sent to the laboratory using the standardised Collect, Drop, Send method. This eliminates the risk of losing diagnostic cells during transfer, a common drawback in traditional methods where up to 37% of samples can be lost with their "rinse and swish" techniques. Apart from this, its innovative technology also enhances the laboratory's ability to create homogenous, thin-layer slides for more accurate results.